Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 8/20 | 0.48 |
| ▸ | CES2 | O00748 | 6/20 | 0.48 |
| ▸ | CES1 | P23141 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28548689 | 0.92 | MAPT (0.50) | MAPTEPHX1FAAHCES2CES1 | |
| SCHEMBL29097175 | 0.83 | MAPT (0.39) | MAPTEPHX1FAAHCES2CES1 | |
| SCHEMBL21567388 | 0.82 | CA2 (0.52) | MAPTEPHX1FAAHCES2CES1 | |
| SCHEMBL23583802 | 0.80 | CA2 (0.55) | MAPTEPHX1FAAHCES2CES1 | |
| SCHEMBL10697627 | 0.78 | MAPT (0.55) | MAPTEPHX1FAAHCES2CES1 | |
| SCHEMBL6265039 | 0.78 | EPHX1 (0.47) | MAPTEPHX1FAAHCES2CES1 | |
| SCHEMBL337512 | 0.77 | MAPT (1.00) | MAPTCES2GPR84FFAR1 | |
| SCHEMBL7461276 | 0.77 | MAPT (1.00) | MAPTCES2GPR84FFAR1 | |
| SCHEMBL21808105 | 0.77 | MAPT (1.00) | MAPTCES2GPR84FFAR1 | |
| SCHEMBL337289 | 0.77 | MAPT (1.00) | MAPTCES2GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | DAVID SAMUEL | 2010-02-25 | — | — | US | disclosed |
| EP-2139836-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | The Royal Institution for the Advancement of Learning/McGill University (CA) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122119-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | PLA2G1B, PLA2G4B, PLA2G2E | MAPT 3875/4885EPHX1 330/4885FAAH 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.